Companies can make mistakes during drug and device development and in the post-marketing maintenance phase, but all too often, organizations apply a temporary solution to the problem and move on. In this article, Helen Lowe at Arriello addresses how Corrective and Preventive Action (CAPA) management provides a better approach to discover the root cause of the problem.
Some key factors that companies should not overlook when developing drug-device products.
Following these strategies will change how your company works with its outsourcing partners.
Developing next-generation technology for medical devices is only half the battle when it comes to being first to market in today’s fast-paced global environment.
It’s not just about architecture; what are the critical systems engineering roles and responsibilities?